SGS successfully implements Oracle Argus solution for drug safety and regulatory compliance
Argus improves the quality and timeliness of safety case processing and reporting, and reduces operational risks for both clinical trial and post-marketed pharmacovigilance data.
SGS has successfully implemented the market leading Oracle Argus database in response to changing pharmacovigilance requirements for processing solicited and unsolicited adverse events (AEs).
Oracle’s Argus Safety is a comprehensive safety database designed specifically to address the complex drug safety and pharmacovigilance requirements of the life sciences industries. The system’s advanced database helps to ensure global regulatory compliance, aid faster and more informed safety decisions, and integrates safety and risk management functions.
Argus provides retrospective and real-time analytics for workflow state, case lock, and expedited report submission compliance, to improve the quality and timeliness of safety case processing and reporting. It also reduces operational risks for both clinical trial and post-marketed pharmacovigilance data.
The multi-tenancy feature in Argus Safety allows multiple SGS clients to reside as separate and unique tenants in a single database with their data completely segregated and restricted to authorized users. This feature also enables SGS to achieve standard configurations, such as code lists, workflow steps, and new user setup across clients, or to have different configurations for specific clients. Additionally, SGS users with greater access can view their work across multiple clients and make more informed decisions.
“We can now use a single database for many clients, which reduces the amount of hardware and resources needed for pharmacovigilance implementation,” commented Rafaël Smets, head of Medical Affairs for SGS. He added “We undertook a careful evaluation of all available systems on the market before selecting Oracle’s flagship safety system. Argus Safety is trusted throughout the life sciences sector for its functionality, reliability, compliance, and ease of use, while ongoing enhancements will meet both regulatory and the industry’s evolving needs”.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.